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Background: We aimed to study the angiogenic profile based on histomorphological markers in endometrial carcinomas in
relation to imaging parameters obtained from preoperative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
and diffusion-weighted imaging (DWI) and to explore the potential value of these markers to identify patients with poor outcome.
Methods: In fifty-four surgically staged endometrial carcinoma patients, immunohistochemical staining with factor VIII and Ki67
allowed assessment of microvessel density (MVD) and microvascular proliferation reflecting tumour angiogenesis. In the same
patients, preoperative pelvic DCE-MRI and DWI allowed the calculation of parameters describing tumour microvasculature and
microstructure in vivo.
Results: Microvascular proliferation was negatively correlated to tumour blood flow (Fb) (r¼  0.36, P¼ 0.008), capillary
permeability surface area product (PS) (r¼  0.39, P¼ 0.004) and transfer from the blood to extravascular extracellular space (EES)
(Ktrans) (r¼  0.40, P¼ 0.003), and was positively correlated to tumour volume (r¼ 0.34; P¼ 0.004). High-tumour microvascular
proliferation, low Fb and low Ktrans were all significantly associated with reduced progression/recurrence-free survival (Po0.05).
Conclusion: Disorganised angiogenesis with coexisting microvascular proliferation and low tumour blood flow is a poor
prognostic factor supporting that hypoxia is associated with progression and metastatic spread in endometrial carcinomas.
Endometrial cancer is the most common pelvic gynaecologic
malignancy in industrialised countries, and the incidence is
increasing (Amant et al, 2005). Treatment and prognosis are
influenced by the surgical International Federation of Gynaecology
and Obstetrics (FIGO) staging system and by histological subtype
and grade (Amant et al, 2005; Pecorelli, 2009). AlthoughB75% of
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the patients have tumours confined to the uterine corpus at the
time of primary diagnosis, suggesting a favourable prognosis,
15–20% of these tumours recur with an aggressive and therapy-
resistant behaviour (Salvesen et al, 2012).
Angiogenesis is essential for tumour growth, invasion and
metastatic spread. Tumour-associated vessels are structurally and
functionally abnormal, typically exhibiting increased permeability,
delayed maturation and potential for rapid proliferation (Fox et al,
2001; Baluk et al, 2003). For endometrial carcinomas, histological
biomarkers reflecting the angiogenic phenotype of the tumour,
such as microvascular density (MVD) and vascular proliferation
have been identified as prognostic markers (Stefansson et al, 2006).
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) is a novel functional imaging technique that allows a
quantitative assessment of tissue perfusion and vascular perme-
ability. This imaging technique enables characterisation of tumour
microvasculature and depiction of the angiogenic profile in vivo
(Tofts et al, 1999; Leach et al, 2012). Diffusion-weighted imaging
(DWI) is another functional MRI technique that characterises
tissue microstructure based on water-diffusion properties, which
are considered surrogate markers of tumour cellularity and cellular
membrane integrity (Padhani et al, 2009). Both functional imaging
methods, when performed as an adjunct to routinely applied
conventional MRI (Amant et al, 2005; Haldorsen and Salvesen,
2012), may provide preoperative functional tumour characterisa-
tion with potential relevance for clinical phenotype and pre-
operative risk stratification in endometrial carcinoma patients.
This study explores the angiogenic profile of tumours based on
histomorphological markers in relation to perfusion/permeability
and diffusion parameters obtained from preoperative functional
MRI in endometrial carcinoma patients. The value of the
histomorphological markers and of functional MRI parameters
in reflecting clinical phenotype, and in identification of patients
with poor outcome in primary endometrial carcinomas, is also
explored.
MATERIALS AND METHODS
Patient series, study setting and clinical outcome. This pro-
spective study was conducted under institutional review board-
approved protocols with informed consent from all patients. From
May 2009 to February 2011 preoperative pelvic MRI, which
included DCE-MRI and DWI was performed in 55 patients in
whom the diagnosis of endometrial carcinoma was subsequently
histologically verified at surgical staging. In 54 (out of 55) patients,
sufficient tumour tissue was available to allow staining with
immunohistochemical markers, and these patients constituted the
study sample (n¼ 54). All patients were diagnosed and treated at
the same university hospital, which is a European Society for
Gynaecologic Oncology accredited cancer centre serving a
population ofB1 million inhabitants.
Follow-up data regarding recurrence, progression and survival
have been collected from patient records and from correspondence
with the responsible primary physicians or gynaecologists. Date of
last follow-up was February 2013 and mean follow-up for survivors
was 23 months (range 6–40).
Histological diagnosis and immunohistochemistry. All patients
were surgically staged according to the revised FIGO staging
system (2009) (Pecorelli, 2009). Surgical specimens were sectioned
along the longitudinal plane of the uterus, and myometrial
invasion and cervical stromal invasion were estimated grossly
and confirmed microscopically according to standard procedures
(Silverberg et al, 2003). Routine histopathology reports were
generated without the knowledge of preoperative MRI findings.
The pathologists documented the numbers and size of metastatic
lymph nodes.
Immunohistochemical staining was performed with factor VIII
and Ki67 enabling calculation of three parameters:
Microvessel density. The average number of microvessels within
selected tumour areas was estimated. Sections were first examined
at low magnifications ( 25,  100) to identify the most vascular
areas of the tumours (i.e., areas with most intense factor VIII
staining and the apparently highest density of microvessels)
(Weidner et al, 1991). Subsequently, 10 fields ( 250; field size,
0.424mm2) were examined, except in a few cases in which less
tumour tissue was available. The counts were expressed as the
average of all fields examined (MVDmean; vessels per mm
2).
Microvascular proliferation. Proliferating endothelial cells
were recognised by their morphology, localisation and distinct
Ki-67/factor VIII co-expression. Positive nuclei outside the
endothelial cell layer, or within the vessel lumen, were avoided.
Microvascular proliferation was expressed as average number
of proliferation microvessels with Ki-67-positive endothelial cells
of all fields examined (proliferating vessels per mm2).
Vascular proliferation index. Vascular proliferation index (VPI)
is expressed by the ratio between the number of proliferating
microvessels with Ki-67-positive endothelial cells (regardless of the
number of positive endothelial cells per vessel) and the total
number of factor VIII-positive microvessels (%), as examined
within selected hotspot areas.
Magnetic resonance imaging protocol. Magnetic resonance
imaging was performed on a 1.5T Siemens Avanto running Syngo
MR B17 (Erlangen, Germany) using a six-channel body coil. Before
imaging, 20mg butylscopolamine bromide (Buscopan, Boehringer
Ingelheim, Germany) was administered intravenously. The proto-
col included standard diagnostic MR imaging based on Guidelines
of the European Society of Urogenital Imaging and functional
imaging (Kinkel et al, 2009), which included DCE-MRI and DWI.
Mean (range) interval between MR examination and surgical
staging was 8.1 (1–36) days.
Structural MRI. This included pelvic sagittal and axial oblique
(perpendicular to the long axis of the uterus) T2-weighted images
and axial oblique T1-weighted gradient-echo images obtained
before and after intravenous contrast administration (Dotarem,
Guerbet: 0.1mmol gadolinium per kilogram of body weight,
3ml s 1 injection speed) using 2-min delay (Haldorsen et al,
2012). In addition, abdominal axial T1-weighted images and axial
and coronal T2-weighted images were acquired up to the renal hila
to assess lumboaortic lymphadenopathy.
Physiological MRI. Pelvic DCE-MRI was acquired with 12 axial
slices using a 3D spoiled gradient echo (FLASH) sequence (echo
time/repetition time (TE/TR)¼ 1.05/2.64ms, flip angle (FA)¼ 121,
matrix¼ 256 256, field of view (FOV)¼ 30 30mm2, slice
thickness¼ 5mm, number of averages (NA)¼ 1) with a temporal
resolution of 2.49 s (Haldorsen et al, 2013). Sequential images were
obtained from 30 s before administration of i.v. contrast to 6.3min
after i.v. contrast, with a pause of 33 s at 2min post contrast (in
order to acquire the diagnostic T1-weighted contrast-enhanced
series). Multiple precontrast images were also acquired with
different FAs of 4, 8, 12 and 151.
Pelvic DWI was acquired using an axial 2D echo planar
imaging (EPI) sequence with b-values of 0 and 1000 smm 2
(TE/TR¼ 79/3100ms, matrix¼ 128 128, FOV¼ 30 30mm2,
slice thickness¼ 5mm, NA¼ 12).
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Data analysis. All images were analysed using NordicICE v.2.3.12
(NordicNeuroLab Inc., Bergen, Norway) by a radiologist (ISH with
47 years of experience with pelvic MR imaging) who was blinded
for tumour stage, histological diagnosis and patient outcome.
Standard images were used in combination with the physiological
images for verification of anatomical structures and tumour
location. Regions of interest (ROIs) were subsequently drawn
manually on one functional image 2min post contrast in each
patient. Regions of interest were drawn directly on the functional
images to avoid registration artefacts between structural and
physiological images.
Two circular ROIs were drawn on the DCE-MRI series on the
same single slice for each patient: ROI no. 1 was placed within the
tumour avoiding necrotic or haemorrhagic areas and ROI no. 2 in
a pelvic artery. The volume of ROI no. 1 had a median of 0.25ml
(mean 0.32ml; range, 0.05–0.96ml) and varied due to variable
tumour size. The quality of the vessel signals in ROI no. 2 differed
substantially between patients, most likely due to turbulence or
flow artefacts. Thus, a population-based vessel signal, which was
individually optimised in each patient using a blind source
separation technique (Gruner and Taxt, 2006; Taxt et al, 2012),
was used.
Because of the high temporal resolution in the dynamic series
(B2.5 s), a two-compartment model incorporating both capillary
flow and permeability was chosen. An in-house implementation of
the adiabatic approximation model of Johnson and Wilson (aaJW)
(St Lawrence and Lee, 1998; Taxt et al, 2012) was thus used to
analyse the contrast concentration curves in the myometrium and
tumour regions in each patient. The time courses in each ROI were
independently interpolated using a cubic spline interpolation
(Matlab v.7.7, Mathworks Inc., Natick, MA, USA) to compensate
for the time gap when the high-resolution T1-weighted images
were acquired. Multiple precontrast flip angle acquisitions were
used to convert from MR signal-intensities to contrast agent
concentrations in time (Taxt et al, 2012). No temporal filtering or
other smoothing was applied to the data. This model allowed
the calculation of four independent parameters describing the
tissue microvasculature: blood flow (Fb), extraction fraction (E),
intravascular/capillary transit time (Tc) and transfer constant from
extravascular extracellular space (EES) to the blood (Kep); and four
derived parameters: blood volume (Vb) (Vb¼ FbTc), volume of
EES (Ve) (Ve¼ (E Fb)/Kep), capillary permeability surface area
product (PS) (E¼ 1 exp(-PS/Fb(1 rHematocrit))) and transfer
from the blood to EES (Ktrans) (Ktrans¼E Fb) (Taxt et al,
2012). Additionally, the integrated area under the concentration
time curve (IAUGC) over 60 and 180 s was calculated to allow a
non-model-based quantitative assessment of tumour enhancement
(Leach et al, 2012).
Values for ADC were measured in ROIs of tumour tissue on the
ADC map. Tumour volume was estimated based on the standard
anatomical images with measurements of maximum tumour
diameter in three orthogonal planes (x, y and z) using the
following equation: Tumour volume¼ x y z/2.
Statistical analysis. The non-parametric Kolmogorov-Smirnov
test for normality was used to verify the normality assumption
for the continuous variables analysed. The correlation between
continuous variables (imaging parameters and angiogenic markers)
was evaluated using the Pearson bivariate correlation test.
Median values were applied to explore the prognostic value of
categories for the imaging parameters and angiogenic markers.
Univariate analyses of time to recurrence (for patients considered
cured by primary treatment) or progression (for patients known to
have residual disease after primary treatment) were performed
using the Kaplan–Meier test. Differences in recurrence-/progres-
sion-free survival were assessed by the Mantel–Cox (log rank)
linear trend test. The Cox proportional hazards model was used to
study the effect on survival of continuous variables. The data
were analysed using SPSS v. 20.0 (Chicago, IL, USA). All reported
P-values were two-sided and considered to indicate statistical
significance when less than 0.05.
RESULTS
Patients. Clinicopathological characteristics are listed in Table 1.
All patients were primarily treated with bilateral salpingo-
oophorectomy and hysterectomy consisting of simple hysterect-
omy in 94% (51/54) and radical hysterectomy in 6% (3/54). Pelvic
lymph node sampling was performed in 89% (48/54) as part of the
routine surgical staging procedure. In 33% (18/54) of the patients
adjuvant therapy was given: 24% (13/55) had chemotherapy and
9% (5/54) had external pelvic radiation.
Median tumour size assessed by structural MRI was 5.9ml
(mean, 31.9; range, 0.1–611.0).
Angiogenic markers based on immunohistochemistry. Median
microvessel density (MVD) was 47 (mean, 49; range, 15–97)
microvessels per mm2. Median microvascular proliferation was
7 (mean, 7.6; range, 0–21) vessels/mm2, whereas median VPI was
3.0% (mean, 4.1%; range, 0–13.6%).
Physiological tumour parameters based on MRI. On the basis of
DCE-MRI the independent physiological parameters reflecting
microvasculature in the tumour tissue had a median of 9.3
(mean, 9.6; range 2.2–17.8) ml per 100mlmin 1 for blood flow
(Fb); 0.39% (mean, 0.39%; range 0.24%–0.67%) for extraction
fraction (E); 14.9 (mean, 15.0; range, 7.5–27.4) seconds for
intravascular capillary transit time (Tc); and 0.29 (mean, 0.30;
range, 0.10–0.55) per min for the transfer constant from EES to
blood (Kep). The derived parameters had a median of 1.9 (mean,
2.2; range, 0.5–5.2) ml per 100ml for blood volume (Vb); 11.9
(mean, 12.6; range, 3.9–29.4) ml per 100ml for fractional volume
Table 1. Clinicopathological patient characteristics
Clinicopathological characteristics n¼54
Age; mean (range) years 67 (41–93)
Postmenopausal, n (%) 48 (89)
Histological subtype, n (%)
Endometrioid 42 (78)
Clear cell 2 (4)
Serous papillary 6 (11)
Carcinosarcoma 3 (6)
Undifferentiated 1 (2)
Tumour grade, n (%)
Grade 1 17 (32)
Grade 2 11 (20)
Grade 3 26 (48)
FIGO stagea, n (%)
1A 23 (43)
1B 14 (26)
2 6 (11)
3B 1 (2)
3C1 4 (7)
3C2 5 (9)
4B 1 (2)
Abbreviation: FIGO¼ International Federation of Gynaecology and Obstetrics.
aAccording to FIGO 2009 staging criteria (Pecorelli, 2009).
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of EES (Ve); 3.3 (mean, 3.4; range, 0.8–7.0) ml per 100mlmin 1
for capillary permeability surface area product (PS); and 2.6 (mean,
2.6; range, 0.6–5.2) ml per 100mlmin 1 for transfer from the
blood to EES (Ktrans). Integrated area under the concentration
time curve in the tumour had a median of 0.51 (mean, 0.57; range,
0.40–1.07) mMs over 60 s and a median of 2.71 (mean, 2.87; range,
1.67–5.02) mMs over 180 s.
Median ADC value in endometrial carcinoma tissue was 0.78
(mean, 0.82; range 0.60–1.20)x10 3mm2s 1.
Correlation between angiogenic markers and imaging para-
meters. Microvascular proliferation was negatively correlated to
tumour blood flow (Fb) (r¼  0.36, P¼ 0.008) (Figure 1A) and
IAUGC over 60 s (r¼  0.28, P¼ 0.04) and 180 s (r¼  0.36,
P¼ 0.007) (Table 2). Microvascular proliferation was also
negatively correlated to capillary permeability surface area product
(PS) (r¼  0.39, P¼ 0.004) and transfer from blood to EES
(Ktrans) (r¼  0.40, P¼ 0.003), and was positively correlated to
tumour volume (r¼ 0.34; P¼ 0.004) (Figure 1B) (Table 2). Similar
but less significant correlations were observed between vascular
proliferation index and tumour capillary permeability surface area
product (PS) and transfer from blood to EES (Ktrans) (P¼ 0.04 for
both).
No significant correlations were observed between the other
physiological imaging parameters and the angiogenic markers;
however, there were tendencies to positive correlation between
microvascular proliferation and capillary transit time (Tc)
(r¼ 0.24, P¼ 0.09) and negative correlations with the transfer
constant from EES to blood (Kep) (r¼  0.22, P¼ 0.10), blood
volume (Vb) (r¼  0.23, P¼ 0.09) and fractional volume of EES
(Ve) (r¼  0.26, P¼ 0.06).
Prognostic value of angiogenic markers and imaging para-
meters. When ranked into two categories (using median limits)
high microvascular proliferation (Figure 2A), high vascular
proliferation index and high MVD were all significantly associated
with reduced progression/recurrence-free survival (Po0.05) in
endometrial carcinomas (Figures 3 and 4). Low tumour blood flow
(Fb) (Figure 2B), low transfer from the blood to EES (Ktrans) and
high capillary transit time (Tc) were also associated with reduced
progression/recurrence-free survival (Po0.05).
When analysing the parameters as continuous variables, blood
flow (Fb) and capillary transit time (Tc) had a significant impact
on recurrence/progression-free survival with univariate hazard
ratios of 0.77 (95% CI, 0.61–0.97; P¼ 0.03) and 1.17 (95% CI,
1.03–1.32; P¼ 0.02), respectively.
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Figure 1. Scatterplots depicting the negative correlation between
microvascular proliferation in tumour tissue and estimated tumour
blood flow (r¼ 0.359, P¼0.008; n¼ 54) (A) and the positive
correlation between microvascular proliferation in tumour tissue
and tumour volume (log scale) (r¼ 0.338, P¼ 0.004; n¼54) (B).
Table 2. Correlation between angiogenesis markers by
immunohistochemistry and imaging markers in tumour tissue-based on
preoperative DCE-MRI (perfusion markers), DWI (diffusion marker) and
conventional MRI (tumour volume) in endometrial carcinomas (n¼54)
Imaging markers
Microvessel
density
ra (Pb)
Microvascular
proliferation
ra (Pb)
Perfusion
Fb; blood flow 0.03 (0.83) 0.36 (0.008)
Tc; capillary transit time 0.04 (0.79) 0.24 (0.09)
E; extraction fraction 0.03 (0.82) 0.00 (0.97)
Kep; transfer constant from EES to
blood
0.15 (0.26) 0.22 (0.10)
Vb; blood volume 0.01 (0.97) 0.23 (0.09)
Ve; fractional volume of EES 0.10 (0.49) 0.26 (0.06)
PS; capillary permeability surface
area product
0.04 (0.79) 0.39 (0.004)
Ktrans; transfer from blood to EES 0.03 (0.84) 0.40 (0.003)
IAUGC over 60 s 0.21 (0.12) 0.28 (0.04)
IAUGC over 180 s 0.15 (0.27) 0.36 (0.007)
Diffusion
ADC value 0.12 (0.38) 0.06 (0.65)
Anatomical imaging
Volume 0.12 (0.39) 0.34 (0.004)
Abbreviations: ADC¼ apparent diffusion coefficient; IAUGC¼ integrated area under the
concentration time curve; DCE-MRI¼dynamic contrast-enhanced magnetic resonance
imaging; DWI,¼diffusion-weighted imaging; EES¼ extravascular extracellular space.
Significant correlations are shown in bold. Independent imaging parameters are listed in
italic.
aPearson correlation coefficient.
bPearson bivariate correlation test.
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DISCUSSION
This is, to our knowledge, the first study comparing measures of
tumour vasculature in vivo based on quantitative DCE-MRI with
measures of intra-tumour angiogenesis in tumour samples in
endometrial carcinoma patients. Interestingly, we found that
prognostic immunohistochemical markers reflecting microvascular
proliferation were significantly correlated to markers of tumour
tissue perfusion and permeability obtained from DCE-MRI
measurements. Furthermore, these DCE-MRI markers also
predicted recurrence/progression-free survival. Thus, we assume
that the increased microvascular proliferation in endometrial
carcinoma tissue detected has its correlate in specific alterations of
the functional status of the tumour vasculature in vivo, with
potential relevance for tumour progression and metastatic spread.
The two-compartment model applied for calculation of the
parameters describing the microvasculature has some inherent
inaccuracies and pitfalls. The use of a population-based arterial
input function may confound the results when the cardiac output
or the vascular resistance differ between patients (Leach et al,
2012). Furthermore, the two-compartment model assumes blood
flow not to be a rate-limiting step; if incorrect, the assessment of
the derived parameters are potentially flawed, and should thus be
interpreted with care. The validity the DCE-MRI parameter Fb in
this study is, however, supported by the finding that estimated
blood flow (Fb) significantly correlated to the non-model-based
parameter IAUGC over 180 s (r¼ 0.53, Po0.001).
Negative correlations between microvascular proliferation and
the DCE-MRI parameter blood flow (Fb) as well as the non-model-
based parameters IAUGC over 60 s and 180 s (Table 2) were
observed, indicating that reduced blood flow is a hallmark of
tumours exhibiting increased microvascular proliferation. Further-
more, microvascular proliferation also negatively correlated with
capillary permeability surface area product (PS) and transfer from
the blood to EES (Ktrans), both parameters being derived from the
blood flow (Fb) and from the extraction fraction (E) reflecting
capillary leakage; thus PS and Ktrans reflect characteristics of both
tumour perfusion and capillary permeability. Although no
correlation was observed between microvascular proliferation and
extraction fraction (E) (Table 2), we found that blood flow (Fb)
and extraction fraction (E) were negatively correlated (r¼  0.34,
P¼ 0.02), suggesting that the tumours with low blood flow have
more leaky vessels.
The observed reduced blood flow accompanied by increased
capillary leakage in tumours with high microvascular proliferation
is somewhat puzzling, but may be related to the fact that tumour
angiogenesis typically generates vessels that in spite of being
numerous, are heterogeneous and coarse making them altogether
dysfunctional (Carmeliet and Jain, 2011). The reduced flow is
considered to be due to the increased leakiness of tumour vessels,
also suggested in our data, through which escaping fluid raises the
interstitial fluid pressure (Carmeliet and Jain, 2011). The notion of
dysfunctional tumour vessels is also supported by the observed
tendency of positive correlation between microvascular prolifera-
tion and capillary transit time (Tc) (Table 2), which is considered a
marker of vessel heterogeneity. Similarly, for rectal cancer a
negative correlation has been observed between MVD (using CD31
staining) and transfer from the blood to EES (Ktrans) at DCE-MRI
(Atkin et al, 2006), suggesting that similar physiological mechan-
isms related to dysfunctional tumour microvasculature may exist
for other tumour types as well.
This study confirms previous findings of a significant prognostic
impact of the histological biomarker reflecting microvascular
proliferation (Stefansson et al, 2006). The negative correlation to
blood flow (Fb) accompanied by the negative prognostic impact of
low tumour blood flow (Fb) suggests that tumour hypoxia may
have a pivotal role in the pathogenic mechanisms leading to
tumour growth and metastatic spread in endometrial cancer.
Tumour hypoxia is described as a characteristic feature of various
solid tumours and is believed to promote tumour progression,
resistance to therapy and transformation to more aggressive
phenotypes (Vaupel and Mayer, 2007; Carmeliet and Jain, 2011).
Preclinical models of cervical cancer and melanoma xenografts
have shown that the highly metastatic tumours have a greater
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Figure 2. Kaplan–Meier curves depicting recurrence/progression-free
survival according to microvascular proliferation (A) and tumour blood
flow (Fb) (B). For each category: number of cases/number of cases with
recurrence or progression. P-values refer to the Log Rank test.
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fraction of hypoxic tissue using pimonidazole as hypoxia marker
(Ovrebo et al, 2012) and lower values for transfer from the blood to
EES (Ktrans) based on DCE-MRI (Ovrebo et al, 2012, 2013), both
supporting hypoxia-associated metastatic spread in these cancer
subtypes. An immunohistochemical study of endometrial carcino-
mas also reported increasingly expressed hypoxia inducible factor-
1a (HIF-1a) from early stages through advanced stages (Ozbudak
et al, 2008), supporting the importance of hypoxia for tumour
progression in endometrial carcinomas.
Interestingly, as opposed to the significant correlations observed
for microvascular proliferation and DCE-MRI parameters, no
correlations were identified for MVD and the DCE-MRI
parameters (Table 2). Thus, we infer that MVD to a lesser extent
reflects the pathophysiology of the angiogenic microvessels than
the amount of proliferating microvessels. Similarly, for breast
cancer the proliferating microvessels reportedly express ongoing
angiogenesis and predicts patient outcome better than the more
commonly used tissue marker MVD (Arnes et al, 2012).
Figure 3. Sagittal (A) and axial (B–E) T2-weighted image (A), DCE image (B) with encircled ROI for calculation of DCE-MRI parameters,
contrast-enhanced T1-weighted image (C), B1000 (D) and ADC map (E) of the uterus and immunohistochemical staining of tumour tissue (F) in a
66-year-old postmenopausal female with an undifferentiated carcinoma (FIGO stage 3C2). The large uterine tumour invading X50% of the
myometrial wall is inhomogeneous and hyperintense (closed arrows) on T2-weighted image (A) and hypointense (closed arrows) relative to the
normal myometrial tissue on DCE image (B) and contrast-enhanced T1-weighted image (C). Calculated tumour blood flow (Fb) in the encircled
ROI (B) was 3.5ml/100ml per minute indicating low blood flow. B1000 (D) depicts hyperintense tumour tissue (arrows) and corresponding
hypointensity on ADC map (E) indicating restricted diffusion with a mean ADC value of 0.60 10 3mm2 s 1 within the encircled ROI (E). Enlarged
metastatic pelvic lymph nodes (B–F; open arrows) and peritoneal fluid in the recto-uterine pouch (A, curved arrow) were identified preoperatively.
Immunohistochemical staining with Ki76/factor VIII (F; magnification  400; arrows depict proliferating cells) showed 21 proliferating vessels
per mm2 indicating high microvascular proliferation in the tumour. The patient was diagnosed with liver and lung metastases 5 months after
primary surgical treatment (simple hysterectomy and bilateral oophorectomy) while still receiving adjuvant chemotherapy (carboplatin/paclitaxel).
Figure 4. Sagittal T2-weighted image (A), fused B1000 and T2-weighted image (B) and immunohistochemical staining of tumour tissue (C) in a
41-year-old premenopausal female with an endometrioid carcinoma (FIGO stage 1A). The tumour (arrows) invadeso50% of the myometrial wall
and is hyperintense on T2-weighted image and exhibits restricted diffusion with a mean ADC value of 0.93 10 3mm2 s 1. Calculated tumour
blood flow (Fb) was 13.5ml per 100ml per minute indicating relatively high blood flow. Immunohistochemical staining with Ki76/factor VIII
(C; magnification 400) showed low microvascular proliferation (0 proliferating vessels per mm2). The patient received primary treatment
with hysterectomy and bilateral oophorectomy and had no signs of recurrence/progression during the following 3 years.
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The observed lack of correlation between tumour ADC value
and microvascular proliferation or MVD (Table 2) suggests that
the tissue-based angiogenic profile of the tumour is only
moderately related to changes in cellular density and extracellular
space, being reflected in the tumour ADC value (Tamai et al,
2007). In line with this, no prognostic value of the preoperative
tumour ADC value in endometrial carcinomas was previously
reported (Haldorsen et al, 2013). Still, the relatively low number of
patients studied calls for caution in the conclusion regarding
negative findings.
This study has some limitations. First, exact colocalisation
between histological sections and DCE-MRI tumour planes for
ROI analyses was not possible, implying that the tumour tissue
examined for microvascular proliferation is not necessarily
included in the tumour volume, in which the functional
characteristics of the vasculature are assessed. However, the ROI
was placed in an apparently representative part of the tumour and
reflects the ‘average’ functional characteristics of the tumour
vasculature in a relatively large tumour volume potentially being
more representative of the vascular profile of the entire tumour.
Second, for calculation of the perfusion and diffusion parameters,
the ROI analysis did not incorporate any spatial information as
opposed to a voxel-by-voxel analysis that could potentially have
detected microvascular heterogeneity. Furthermore, histogram
analyses of the ROIs could potentially have provided additional
information regarding the extent of tumour heterogeneity, which
has been shown to yield prognostic information in various other
malignant tumours (Davnall et al, 2012). The current approach
was, however, chosen due to the higher signal-to noise ratio
ensuring more reliable quantitative parameter estimations. Third,
the analysed ROIs did not comprise the entire tumour volume, as
the ROIs were drawn on a single slice and the periphery of the
tumour as well as necrotic areas were intentionally excluded from
the ROIs. This was, however, done in order to limit the inclusion of
the necrotic tissue or normal myometrial tissue (that would
otherwise be included due to minimal temporal changes in uterine
position due to arterial pulsation and bowel peristalsis) in the
analysed ROIs.
In summary, endometrial carcinomas that exhibit increased
microvascular proliferation have lower tumour blood flow (Fb)
in vivo assessed by DCE-MRI. Both microvascular proliferation
and tumour blood flow have a significant impact on recurrence/
progression-free survival in endometrial carcinomas. Our findings
are consistent with the hypothesis that disorganised angiogenesis
with coexisting vascular proliferation and hypoxia promotes
tumour progression and metastatic spread in endometrial
carcinomas. Dynamic contrast-enhanced magnetic resonance
imaging may offer a potential for early prediction of angiogenesis-
related resistance to treatment (Wilson and Hay, 2011) or response
to drugs targeting angiogenesis, but further studies in patients
undergoing such treatment are needed to assess the clinical
applicability.
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